Text Size

Human Tumor Sequencing Project (HuTS)

This study is currently recruiting participants.
Verified December 2012 by Scripps Translational Science Institute
Sponsor:
Information provided by (Responsible Party):
Eric Topol, MD, Scripps Translational Science Institute
ClinicalTrials.gov Identifier:
NCT01608230
First received: May 25, 2012
Last updated: December 11, 2012
Last verified: December 2012
History of Changes
  Purpose

This study is being done to learn more about genetic mutations in cancer cells and to find out how the development of new technologies can increase knowledge of these mutations and possibly predict an individual's response to certain treatments.


Condition
Cancer

Study Type: Observational
Study Design: Observational Model: Case-Only
Time Perspective: Prospective
Official Title: Human Tumor Sequencing Project

Resource links provided by NLM:

MedlinePlus related topics: Cancer
U.S. FDA Resources

Further study details as provided by Scripps Translational Science Institute:

Primary Outcome Measures:
  • Determine biomarkers of clinical utility and copy number variants through genetic analysis. [ Time Frame: four years ] [ Designated as safety issue: No ]

Estimated Enrollment: 100
Study Start Date: April 2010
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Cancer

Criteria

Inclusion Criteria:

  • Diagnosis of a solid tumor or blood borne cancer
  • 18 years or older
  • Eligible to have blood drawn
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01608230

Contacts
Contact: Sharon Haaser, RN, BSN 858-554-5758 haaser.sharon@scrippshealth.org

Locations
United States, California
Scripps Translational Science Institute Recruiting
La Jolla, California, United States, 92037
Contact: Sharon Haaser, RN, BSN     858-554-5758     haaser.sharon@scrippshealth.org    
Principal Investigator: Eric Topol, MD            
Sponsors and Collaborators
Scripps Translational Science Institute
  More Information

No publications provided

Responsible Party: Eric Topol, MD, Director, Scripps Translational Science Institute
ClinicalTrials.gov Identifier: NCT01608230     History of Changes
Other Study ID Numbers: 09-5270
Study First Received: May 25, 2012
Last Updated: December 11, 2012
Health Authority: United States: Institutional Review Board

ClinicalTrials.gov processed this record on June 17, 2013